(NASDAQ: IMMP) Immutep's forecast annual revenue growth rate of -30.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Immutep's revenue in 2025 is $6,920,900.On average, 1 Wall Street analysts forecast IMMP's revenue for 2025 to be $5,516,684,489, with the lowest IMMP revenue forecast at $5,516,684,489, and the highest IMMP revenue forecast at $5,516,684,489. On average, 1 Wall Street analysts forecast IMMP's revenue for 2026 to be $3,682,641,625, with the lowest IMMP revenue forecast at $3,682,641,625, and the highest IMMP revenue forecast at $3,682,641,625.
In 2027, IMMP is forecast to generate $3,682,641,625 in revenue, with the lowest revenue forecast at $3,682,641,625 and the highest revenue forecast at $3,682,641,625.